[Hematological Evaluation and Monitoring in Adult Patients Diagnosed With Schizophrenia].

Autor:	Tamayo Martínez N; Médica psiquiatra, candidata a magístra Epidemiología Clínica. Pontificia Universidad Javeriana, Bogotá, Colombia., Bohórquez Peñaranda AP; Médica psiquiatra, magístra en Epidemiología Clínica. Profesora asistente del departamento de Psiquiatría y Salud Mental. Pontificia Universidad Javeriana, Bogotá, Colombia., García Valencia J; Médica psiquiatra, Doctora en Epidemiología Clínica. Profesora titular del Departamento de Psiquiatría, Facultad de Medicina. Universidad de Antioquia., Medellín, Antioquia, Colombia., Jaramillo González LE; Médico psiquiatra, Master en Farmacología. Profesor Universidad Nacional de Colombia, Bogotá, Colombia., Ávila MJ; Médico Servicio Social Obligatorio. Pontificia Universidad Javeriana, Bogotá, Colombia., Gómez-Restrepo C; Médico psiquiatra, psicoanalista, psiquiatra de enlace, magíster en Epidemiología Clínica. Profesor titular y Director del Departamento de Epidemiología Clínica y Bioestadística. Pontificia Universidad Javeriana. Hospital Universitario San Ignacio., Bogotá, Colombia. Electronic address: cgomez@javeriana.edu.co., Arenas González ML; Médico, Residente de Psiquiatría General, Pontificia Universidad Javeriana, Bogotá, Colombia.
Jazyk:	Spanish; Castilian
Zdroj:	Revista colombiana de psiquiatria [Rev Colomb Psiquiatr] 2015 Jul-Sep; Vol. 44 (3), pp. 131-6. Date of Electronic Publication: 2015 Jun 23.
DOI:	10.1016/j.rcp.2015.05.007
Abstrakt:	Objectives: To guide the clinician in taking decisions on the best strategies for assessing and monitoring the risk of blood disorders in adults diagnosed with schizophrenia in pharmacological treatment. Method: A clinical practice guideline was developed following the guidelines of the Methodological Guide of the Ministry of Social Protection to collect evidence and grade recommendations. De novoliterature researchwas performed. Results: With the use of antipsychotics there isriskofreducción in the leukocyte count and the risk of agranulocytosis,the later associated with the use of clozapine, although it is a rare event(0.8%) can be fatal; this effect occurs most frequently in the first twelve weeks of treatment and the risk is maintained aroundthe first year of it. Conclusion: The recommendations were considered strongin all hematologic related monitoring.A blood count should be taken at the start of pharmacological treatment. If the patient is started on clozapine one shouldbe taken weekly during the first three months, monthly until completing one year and every six months thereafter. If there is a decrease in white blood cell count the patient should be monitored regularly, stopping if is a less than 3,500 cells/mm(3) and consider referral if is less than 2,000 cells/mm(3). (Copyright © 2014 Asociación Colombiana de Psiquiatría. Publicado por Elsevier España. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu